Clinical Trial Update: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study [Phase 1]

View source ↗

Summary

Phase 1 study exploring cannabidiol as a novel-type antipsychotic with a focus on drug delivery and drug–drug interactions in schizophrenia. The trial has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Central Institute of Mental Health, Mannheim | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED